Racura Oncology LtdASX: RAC

Race reveals new strategy for cancer drug Bisantrene

· Issued by Racura Oncology Ltd

Filed with ASX · · 27 pages · English

The strategy defines five paths for the clinical development of Bisantrene that greatly expands the addressable market for Bisantrene while reducing clinical development risk and targeting cancers beyond Acute Myeloid Leukaemia (AML). The new strategy builds on the value embedded in Bisantrene from its use in more than 40 prior human trials across a range of cancers. Race Oncology will continue to

Racura Oncology Ltd on 6ix

Earlier from Racura Oncology

Later from Racura Oncology

All Racura Oncology news releases